Investigator Studies Program (MISP): Diabetes and Metabolism
Effective January 2019, the Diabetes & Metabolism Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to February 11, 2019 for the first review cycle, up to June 16, 2019 for the second review cycle and up to October 10, 2019 for the third review cycle. This is a competitive process; decisions will be made on the basis of scientific merit and strategic fit within the AOI.

The following areas are of interest to the Investigator Studies Program Committee:

  • Use (e.g., ease of utilization, patient preference, adherence, compliance) and effects of DPP-4 inhibitors and SGLT-2 inhibitors, alone or in combination, and impact of adding / switching within and across classes of oral and injectable anti-hyperglycemic medications on relevant outcomes in the real world
  • Effects of DPP-4 inhibitors and SGLT-2 inhibitors on body weight and obesity-associated complications in T2DM in the real world
  • Clinical and mechanistic studies regarding the effects of SGLT-2 inhibition on macrovascular complications including heart failure in patients with or without T2DM
  • Clinical and mechanistic studies regarding the effects of SGLT-2 inhibition on renal function in patients with or without T2DM
  • Clinical and mechanistic studies regarding the effects of SGLT-2 inhibition on other comorbidities frequently associated with T2DM
  • Clinical and mechanistic studies regarding the effects of SGLT-2 inhibition, alone and in combination with DPP-4 inhibitors, on metabolic control and the cardio-renal axis in T2DM
  • Impact of genetic, ethnic, geographic, and dietary factors on the efficacy and safety of SGLT-2 inhibitors
  • Effects of SGLT-2 inhibition and GLP-1 RA in combination on metabolic regulators, substrate metabolism, volume status, renal, and cardiac function, and CV outcomes
  • Mechanisms regulating glucagon secretion in T2DM and the impact of treatment modalities
  • Effect of glucagon, alone and in combination with GLP-1, on energy balance and non-alcoholic fatty liver disease in humans
  • Metabolic determinants of NASH

Please complete a full protocol and detailed budget via Visiontracker, the Company's on-line study management system (in US) or your MSD country representative (outside US). The proposals will be collectively reviewed and selected by the Diabetes and Metabolism MISP Committee.



MISP Information
This site is intended for US investigators only. Investigators outside of the US interested in submitting research proposals to the Investigator Studies Program should contact their local MSD office.